

## Dabrafenib (GSK2118436), B-Raf mutant inhibitor

Catalog	Unit
TBI1569-5MG	5 mg
TBI1569-25MG	25 mg

### Product Details

**Formal Name:** N-[3-[5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-4-thiazolyl]-2-fluorophenyl]-2,6-difluorobenzenesulfonamide

**Alternate Names:** GSK2118436

**Molecular Formula:** C<sub>23</sub>H<sub>20</sub>F<sub>3</sub>N<sub>5</sub>O<sub>2</sub>S

**Formula Weight:** 519.56

**CAS Number:** 1195765-45-7


**Purity:** >98%

**Formulation:** powder

**Solubility:** Soluble in DMSO (up to 30 mg/ml), or in Ethanol (up to 1 mg/ml with warming).

**Storage:** -20°C

**Stability:** ≥ 1 year.



### Applications

B-Raf mutant inhibitor

### Functions

Dabrafenib is a selective inhibitor of mutant B-RafV600E (IC<sub>50</sub> = 0.8 nM), with 4- and 6-fold reduced potency against wild type B-Raf and c-Raf (IC<sub>50</sub> = 3.2 and 5 nM, respectively). Has been in clinical trials in patients with B-RafV600E metastatic melanoma and other solid tumors. Endoplasmic reticulum stress and autophagy are induced in melanoma cells after treatment with dabrafenib and protect cells from dabrafenib toxicity. Induces epithelial differentiation in BRAF-mutant colorectal cancer cells.

### Application Procedures

First dissolved in DMSO (up to 30 mg/ml), or in Ethanol (up to 1 mg/ml with warming), then diluted to aqueous buffer. Solutions in DMSO or ethanol may be stored at -20°C for up to 3 months.

**For research use only.**